Latest Breaking News On - Group demonstrated strong treatment - Page 1 : comparemela.com

Bexotegrast demonstrated statistically significant increase in FVC at 4, 8 and 12 weeks of treatment, outperforming lower dose groups No.

Group demonstrated strong treatmentPliant therapeutics incBexotegrast clinical development nextQuantitative lung fibrosisWell toleratedSerious adverseGroup demonstrated strong treatment effectsProfibrotic biomarkers versus placeboMixed model repeat measures analysisModified intentForced vital capacityNasdaq plrxPliant therapeutics